Mohs Surgery: How It Works and When It Is Used

Mohs micrographic surgery is a specialized technique for removing certain skin cancers with the highest available cure rates while preserving the maximum amount of surrounding healthy tissue. This page covers the procedural mechanics, clinical indications, classification boundaries, established tradeoffs, and common misconceptions associated with the technique. The procedural framework is grounded in pathology-confirmed margin analysis, distinguishing Mohs from standard excision in both method and outcome profile.

Definition and Scope

Mohs micrographic surgery is a tissue-sparing excision technique in which a trained surgeon removes skin cancer in successive horizontal layers, examining 100% of the surgical margin under a microscope before each subsequent layer is taken. The procedure is named after Frederic E. Mohs, who developed the original fixed-tissue technique at the University of Wisconsin in the 1930s; the modern fresh-tissue variant, refined through the 1970s, is the standard form practiced today.

The American College of Mohs Surgery (ACMS) defines fellowship training as a minimum of 1 year of supervised procedural training following dermatology residency, with fellows performing at least 500 cases under direct supervision. The American Academy of Dermatology (AAD) and the American Society for Dermatologic Surgery (ASDS) recognize Mohs micrographic surgery as the treatment of choice for high-risk nonmelanoma skin cancers at specific anatomical sites.

The scope of Mohs surgery in the United States encompasses primarily basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), which together account for the overwhelming majority of nonmelanoma skin cancers diagnosed annually. The Skin Cancer Foundation reports that BCC is the most frequently diagnosed cancer in the United States, with more than 3.6 million cases diagnosed per year (Skin Cancer Foundation, Basal Cell Carcinoma). Mohs surgery carries 5-year cure rates of up to 99% for primary BCC (AAD, Mohs Surgery), making it the benchmark against which other excision techniques are measured.

For a broader overview of skin cancer types and their clinical significance, the skin cancer types and warning signs reference covers the full diagnostic spectrum.

Core Mechanics or Structure

The procedural structure of Mohs surgery differs from standard surgical excision in one defining way: pathological margin assessment occurs intraoperatively, not after the specimen has been processed by an off-site laboratory.

Stage-by-stage tissue removal follows this sequence:

  1. The visible tumor and a thin margin of surrounding tissue are excised as a horizontal disc.
  2. The specimen is mapped with orientation markers (ink or suture) that correspond to a hand-drawn diagram of the surgical site.
  3. The tissue is processed using cryosection technique: the disc is flattened, frozen, sectioned, and stained — most commonly with hematoxylin and eosin (H&E) — to produce a slide that displays the entire peripheral and deep margins simultaneously.
  4. The Mohs surgeon, functioning as both surgeon and pathologist in this context, examines the slide microscopically.
  5. If cancer cells are identified at any margin, their location is mapped precisely using the orientation diagram.
  6. Only the tissue corresponding to the positive margin zone is re-excised, and the process repeats.
  7. When all margins are confirmed clear, the wound is ready for reconstruction.

This intraoperative loop is the mechanistic advantage of the procedure. Standard wide local excision sends tissue to an external pathology laboratory using bread-loaf sectioning, which samples only 1–2% of the actual margin surface (ACMS, Technical Standards). Mohs cryosectioning examines 100% of the margin, which is the direct source of its superior recurrence data.

The Mohs surgeon's dual role — excising tissue and reading the pathology slide — is a board-recognized subspecialty competency governed by procedural guidelines from both the ACMS and the AAD.

Causal Relationships or Drivers

Several tumor-level and patient-level variables drive the clinical decision to use Mohs surgery rather than standard excision or other modalities such as cryotherapy in dermatology or phototherapy for skin conditions.

Tumor geometry and subclinical spread are the primary causal drivers. BCC and SCC can extend along fascial planes, nerves (perineural invasion), or vascular structures well beyond what is visible clinically or dermoscopically. Aggressive histological subtypes — including morpheaform (sclerosing), infiltrative, and micronodular BCC — are associated with subclinical extension distances of 5–15 mm beyond the clinical margin in a significant proportion of cases (per AAD Clinical Guidelines for Nonmelanoma Skin Cancer).

Anatomical site drives Mohs selection at locations where tissue preservation is critical to function or aesthetics: the nose, eyelids, ears, lips, hands, feet, and genitalia. These areas are designated as H-zone (high-risk zone) sites in the AAD/ACMS appropriate use criteria.

Recurrence after prior treatment is a strong independent driver. Recurrent tumors have disrupted tissue planes that obscure residual disease; cure rates for recurrent BCC with standard excision fall to approximately 60%, compared to up to 94% with Mohs surgery (AAD).

Regulatory and coding context also shapes utilization. CPT codes 17311–17315 govern Mohs surgery billing, with each additional stage coded separately. The regulatory context for dermatology page covers the broader compliance framework within which dermatologic procedures including Mohs are performed in the United States.

Classification Boundaries

Mohs surgery is not appropriate for all skin cancers. The AAD and ACMS published Appropriate Use Criteria (AUC) in 2012, subsequently updated, that define the boundaries of indicated use across tumor type, size, location, histology, and patient factors.

Tumors typically within Mohs AUC:
- BCC and SCC at high-risk anatomical sites (H-zone)
- Tumors with aggressive histological subtypes (morpheaform, infiltrative, desmoplastic SCC)
- Recurrent tumors after prior excision or radiation
- Tumors with perineural or perivascular invasion on prior biopsy
- Tumors in immunocompromised patients (organ transplant recipients, patients on immunosuppressant therapy)
- Dermatofibrosarcoma protuberans (DFSP), a rare soft tissue tumor for which Mohs has demonstrated high cure rates

Tumors typically outside Mohs AUC:
- Melanoma (standard Mohs is generally not indicated; staged excision protocols exist but differ mechanistically)
- Superficial BCC in low-risk trunk or extremity locations measuring less than 2 cm in diameter
- Merkel cell carcinoma (managed with wide excision and sentinel lymph node biopsy per National Comprehensive Cancer Network [NCCN] guidelines)

The boundary distinction between Mohs and standard excision is not purely oncological — it incorporates site, size, depth, histology, and prior treatment history as a composite index. The skin biopsy: what to expect reference describes how initial biopsy histology informs subsequent surgical planning.

Tradeoffs and Tensions

Time and facility requirements represent the most significant operational tension. A single-stage Mohs procedure with a clear margin may be completed in 2–3 hours; a multi-stage case requiring 3 or 4 stages can extend to a full clinical day. This is intrinsic to the intraoperative pathology model and is not reducible without compromising the margin-analysis methodology.

Cost relative to standard excision is a documented tension in the surgical economics literature. A single-stage Mohs procedure carries a higher per-encounter cost than standard excision; however, modeling studies published in the Journal of the American Academy of Dermatology have argued that reduced recurrence rates lower total lifetime treatment costs for high-risk tumors.

Reconstruction complexity is deferred until margin clearance is confirmed, which means wound reconstruction — sometimes requiring flaps or grafts — occurs on the same day as excision. This creates surgical complexity and patient burden (prolonged chair time) that is absent from procedures where reconstruction is staged separately.

Surgeon credentialing variability is a recognized tension. The ACMS fellowship pathway is one recognized credentialing route, but other training pathways exist, and not all practitioners performing Mohs-labeled procedures have equivalent fellowship training. The AAD has published position statements addressing training standards, though no federal regulatory body mandates specific credentialing for the procedure itself.

Appropriate use expansion and overuse concerns have been raised in the peer-reviewed literature. A study published in JAMA Dermatology (Linos et al., 2012) found geographic variation in Mohs surgery rates that was not fully explained by tumor burden, raising questions about whether AUC boundaries are consistently applied across practice settings.

Common Misconceptions

Misconception: Mohs surgery is suitable for all skin cancers.
Correction: Mohs surgery has defined AUC boundaries. Melanoma, Merkel cell carcinoma, and low-risk superficial BCC on the trunk are typically managed with other modalities. Application outside AUC boundaries is documented in the literature as a point of clinical debate.

Misconception: More stages always mean worse outcomes.
Correction: The number of stages reflects subclinical tumor extent, not surgical error. A 3-stage case simply means residual tumor was present at the margin after stages 1 and 2. Margin clearance at any stage is the therapeutic endpoint.

Misconception: The procedure requires general anesthesia.
Correction: Mohs surgery is performed under local anesthesia in an outpatient office setting. General anesthesia is not standard, and the procedure is not performed in a hospital operating room for the vast majority of cases.

Misconception: Mohs surgery eliminates all recurrence risk.
Correction: 5-year cure rates for primary BCC reach up to 99%, but residual risk exists, particularly for recurrent tumors, immunocompromised patients, and rare aggressive histological variants. Post-procedural surveillance remains part of the clinical management pathway.

Misconception: The Mohs surgeon and the pathologist are different people.
Correction: In the Mohs model, the operating surgeon personally prepares, reads, and interprets the cryosection slides. This dual-role competency is the defining procedural feature and the source of both its precision and its credentialing requirements.

Checklist or Steps (Non-Advisory)

The following sequence represents the established procedural framework for a standard Mohs micrographic surgery encounter, as described in ACMS and AAD procedural literature.

Pre-procedural phase:
- [ ] Confirm biopsy-proven diagnosis and histological subtype documented in the medical record
- [ ] Review anatomical site classification against AUC criteria
- [ ] Document prior treatments and recurrence history if applicable
- [ ] Verify that imaging (where indicated for deep or extensive tumors) has been completed
- [ ] Confirm patient medication list for anticoagulants and antiplatelet agents (surgical team documentation step)

Intraoperative phase:
- [ ] Demarcate clinical tumor margins under adequate lighting with or without dermoscopic assistance
- [ ] Administer local anesthesia to the surgical field
- [ ] Excise the first-stage tissue disc with beveled peripheral margins at approximately 45 degrees
- [ ] Apply orientation markers (ink, sutures, or staples) consistent with the mapping diagram
- [ ] Process cryosections for the complete peripheral and deep margin
- [ ] Microscopically examine all sections; document findings on the stage map
- [ ] If positive margins identified: re-excise only the positive zone and repeat processing
- [ ] If all margins clear: proceed to wound assessment for reconstruction planning

Post-procedural phase:
- [ ] Reconstruct wound using primary closure, flap, graft, or second-intention healing as clinically indicated
- [ ] Apply wound dressing per surgeon protocol
- [ ] Schedule follow-up for wound check and post-treatment surveillance

Reference Table or Matrix

Variable Standard Wide Local Excision Mohs Micrographic Surgery
Margin assessment method Bread-loaf sectioning (~1–2% of margin examined) Cryosection horizontal mapping (100% of margin examined)
Pathology timing Post-operative (1–3 business days) Intraoperative (same day)
Anesthesia Local or general depending on size/site Local anesthesia, outpatient
Cure rate: primary BCC ~90–95% (5-year) Up to 99% (5-year)
Cure rate: recurrent BCC ~60% (5-year) Up to 94% (5-year)
Tissue preservation Wider margins excised conservatively Minimal tissue removed per stage
Primary indication Low-risk BCC/SCC at non-critical sites High-risk, recurrent, or H-zone tumors
Reconstruction timing Can be immediate or staged separately Same day, after margin clearance confirmed
Surgeon-pathologist role Separate roles (external lab) Single surgeon performs both functions
Setting Office or hospital operating room Office-based surgical suite
Governing appropriate-use criteria AAD Clinical Guidelines AAD/ACMS Appropriate Use Criteria (AUC)

For patients seeking to understand the broader landscape of dermatologic procedures and how Mohs fits within subspecialty practice, the index page provides a structured entry point to the full reference library on this site.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)